Roche Holding AG (XSWX:ROP) Research & Development: CHF13,352 Mil (TTM As of Dec. 2025)


XSWX:ROP Roche Holding AG XSWX:ROP
79 GF Score
Price CHF332.00
GF Value CHF264.69
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Roche Holding AG Research & Development?

Roche Holding AG XSWX:ROP +2.09% 79 Research & Development is CHF13,352 Mil as of Dec. 2025. GuruFocus rates XSWX:ROP with a GF Score™ of 79/100 and a GF Value™ of CHF264.69 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Roche Holding AG's Research & Development for the six months ended in Dec. 2025 was CHF6,676 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was CHF13,352 Mil.

Roche Holding AG  (XSWX:ROP) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Roche Holding AG Research & Development Related Terms

Roche Holding AG Research & Development Historical Data

* Premium members only.

The historical data trend for Roche Holding AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roche Holding AG Research & Development Chart

Roche Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14,799.00 15,225.00 14,200.00 15,304.00 13,352.00

Roche Holding AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,282.00 7,388.00 7,916.00 6,676.00 6,676.00
XSWX:ROP
79GF Score
Roche Holding AG XSWX:ROP
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roche Holding AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF13,352 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of CHF13,352 Mil mean?
Roche Holding AG (XSWX:ROP) has a Research & Development of CHF13,352 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Roche Holding AG and its competitors.
Is Roche Holding AG's Research & Development too high?
Roche Holding AG's current Research & Development is CHF13,352 Mil. Overall, Roche Holding AG has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's Research & Development compare to LLY and JNJ?
Roche Holding AG's Research & Development of CHF13,352 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Roche Holding AG and its competitors. Roche Holding AG's current Research & Development is CHF13,352 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:ROP) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF264.69, compared to a current price of CHF332.00 — trading 25.4% above its estimated fair value. The current Research & Development is CHF13,352 Mil. Roche Holding AG's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Roche Holding AG (XSWX:ROP), the current Research & Development is CHF13,352 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roche Holding AG (XSWX:ROP) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of CHF332.00 is trading 25.4% above its estimated GF Value™ of CHF264.69. GuruFocus considers Roche Holding AG to be Modestly Overvalued.

Key valuation signals for XSWX:ROP:

  • Research & Development: CHF13,352 Mil
  • GF Value™: CHF264.69 vs. price of CHF332.00 (25.4% above fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the XSWX:ROP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
79GF Score

Get the complete analysis for XSWX:ROP

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF332.00
Price
CHF264.69
GF Value